title: Influence of tamoxifen on carotid intima-media thickness in postmenopausal women.
abstract: BACKGROUND
  Intima-media thickness of the common carotid artery (IMT-CCA) is an early marker of atherosclerosis. Tamoxifen is a selective estrogen-receptor modulator with estrogen-like effects on cardiovascular risk factors but as-yet unexplored effects on carotid artery structure. The goal of this study was to determine the influence of tamoxifen on IMT-CCA in menopausal women.
  
  
  RESULTS
  With a predefined calculation of the sample size, 67 menopausal women with cancer who were treated with tamoxifen for > or =1 year and 37 menopausal women with cancer who were never treated with tamoxifen were enrolled. IMT-CCA, internal diameter, and pulse pressure were determined with a high-definition echotracking device and applanation tonometry in a central core laboratory that was blinded to treatment. Both groups were similar for clinical characteristics, including cardiovascular risk factors. IMT and internal diameter were significantly lower in the tamoxifen group (mean duration of treatment, 2.4+/-0.9 years) than in the control group (609+/-117 microm versus 662+/-147 microm, P=0.04, and 4.89+/-0.60 mm versus 5.12+/-0.58 mm, P=0.03, respectively). Pulse pressure was not influenced by the use of tamoxifen. After adjustment for age, cardiovascular risk factors, carotid pulse pressure, duration of menopause, and previous use of hormone replacement therapy, IMT remained significantly lower among tamoxifen users (P<0.00001), with an impact on IMT (-70 microm) equivalent to spontaneous evolution with 12 years of aging (5 microm/y).
  
  
  CONCLUSIONS
  The use of tamoxifen was associated with a significantly lower carotid IMT in menopausal women with cancer. Randomized trials are needed to confirm the cardioprotective effect of selective estrogen-receptor modulators in terms of prevention of atherosclerosis.
authors.affiliation: Department of Pharmacology, St Antoine University-Hospital, Paris, France. tabassome.simon@chusa.jussieu.fr
authors.forename: T
authors.initials: T
authors.lastname: Simon
authors.forename: P
authors.initials: P
authors.lastname: Boutouyrie
authors.forename: J M
authors.initials: JM
authors.lastname: Simon
authors.forename: B
authors.initials: B
authors.lastname: Laloux
authors.forename: C
authors.initials: C
authors.lastname: Tournigand
authors.forename: A I
authors.initials: AI
authors.lastname: Tropeano
authors.forename: S
authors.initials: S
authors.lastname: Laurent
authors.forename: P
authors.initials: P
authors.lastname: Jaillon
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy*; D002339:Carotid Arteries / Q000000981:diagnostic imaging / Q000187:drug effects*; D005260:Female; D006801:Humans; D008593:Menopause / Q000187:drug effects; D008875:Middle Aged; D017698:Postmenopause; D012307:Risk Factors; D018401:Sample Size; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage; D013629:Tamoxifen / Q000008:administration & dosage*; D017539:Tunica Intima / Q000000981:diagnostic imaging / Q000187:drug effects*; D017540:Tunica Media / Q000000981:diagnostic imaging / Q000187:drug effects*; D014463:Ultrasonography
chemical_list: D018931:Antineoplastic Agents, Hormonal; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen